AYTU BioPharma (AYTU) Stock: Buy, Sell, or Hold?
AYTU - AYTU BioPharma, Inc. Common Stock
$1.90
-0.08 (-4.04%)
▼
5d:
-6.86%
30d:
-17.75%
90d:
-7.77%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 12, 2026
16d
Get Alerted When AYTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AYTU shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AYTU shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: AYTU is currently trading at $1.90, which is considered oversold relative to its 30-day fair value range of $1.97 to $2.18. From a valuation perspective, the stock is trading at a discount (Forward PE: -25.3) compared to its historical average (14.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AYTU is in a downtrend. The price is currently testing key support at $1.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: AYTU scores 87/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.67 (+408.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AYTU is in a downtrend. The price is currently testing key support at $1.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.0% recently.
Market Sentiment: AYTU scores 87/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.67 (+408.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.97 -
$2.18
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (87/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.0%)
- BULLISH: Trading 408.8% below Wall St target ($9.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.97 -
$2.18
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.90
Resistance Level
$2.14
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.33
Wall Street Target
$9.67
(+408.8%)
Revenue Growth (YoY)
6.4%
Profit Margin
-24.8%
PE vs Historical
-25.3 vs 14.8
CHEAP
Share & Embed Analysis
Last updated: October 26, 2026 3:54 AM ET
Data refreshes hourly during market hours. Next update: 4:54 AM
Data refreshes hourly during market hours. Next update: 4:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AYTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$206 | 56 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
20 analysts |
$56 | 38 SELL |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$30 | 47 HOLD |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$43 | 54 HOLD |
